Table 4– Patients receiving specific anti-tuberculosis (TB) drugs analysed by extensively drug-resistant (XDR)-TB patient group
XDR aloneXDR+2sliXDR+sliG4XDR+sliG4EZ
Subjects n301684842
Group 1
 Pyrazinamide54497369
 Ethambutol43375048
Group 2
 Ofloxacin58697774
 Later generation fluoroquinolones171667
Group 3
 Kanamycin37125448
 Amikacin13622
 Capreomycin39691517
 Streptomycin206810
Group 4
 Group 4, any drug96948381
 Ethionamide or protionamide79767574
 Cycloserine or terizidone88884848
 Para-aminosalycilic acid65572931
Group 545511719
  • Data are presented as %, unless otherwise stated. XDR alone: resistance to isoniazid and rifampicin, plus any fluoroquinolone and any second-line injectable drug (sli); XDR+2sli: XDR-TB, plus resistance to both an aminoglycoside injectable (kanamycin/amikacin) and to capreomycin; XDR+sliG4: XDR-TB, plus resistance to all second-line TB drugs tested, with, as a minimum, resistance to kanamycin and to at least one group 4 (G4) drug; XDR+sliG4EZ: XDR-TB, plus resistance to all first- and second-line TB drugs tested, with, as a minimum, resistance to kanamycin, one group 4 drug and either pyrazinamide (Z) and/or ethambutol (E).